Background: Highly active antiretroviral therapy for HIV-infected patients causes metabolic changes known as the lipodystrophy syndrome. Autologous fat injections, dermal fat grafts, malar implants and injected fillers have been reported as treatment options.
Objective: To evaluate the results of HIV-infected patients treated with Bio-Alcamid for facial lipoatrophy.
Methods And Materials: Over a 3-year period, 13 HIV-infected patients with facial lipoatrophy had Bio-Alcamid injections for aesthetic purposes. The procedure was done under local anesthesia, and the amount of the injected material varied from 5 to 13 ml. Results were independently evaluated by patients and physicians.
Results: Most of the patients felt they had good to excellent results. Touch-ups were necessary for 2 patients; the added volume was 2-3 ml for each. No major complications were recorded. A small hematoma was noted in 1 patient. Overcorrection was attained in 2 cases, and some of the filler was removed at the patient's request.
Conclusion: One of the greatest advantages of this filler is that, although permanent, it can be removed easily. We consider Bio-Alcamid to be a safe and useful correcting tool for patients suffering from drug-induced facial lipoatrophy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000098575 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ptosis in human immunodeficiency virus-infected patients under long-term antiretroviral treatment.
Clin Neurol Neurosurg
December 2024
Department of Neurosciences and Mental Health, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal; Faculdade de Medicina-Instituto de Medicina Molecular, Centro de Estudos Egas Moniz, Universidade de Lisboa, Lisbon, Portugal.
Objective: To present cases of ptosis in HIV-1 patients on long-term antiretroviral therapy (ART) and review the existing literature.
Methods: Five HIV-1-positive patients with slowly progressive bilateral ptosis underwent a comprehensive diagnostic evaluation, including imaging studies, neurophysiological testing, muscle biopsy, and genetic analysis. A literature review was conducted.
Case Report: Concurrent pathogenic variants in the gene as a cause of sporadic partial lipodystrophy.
Front Genet
November 2024
Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Introduction: Inherited lipodystrophies are a group of rare diseases defined by severe reduction in adipose tissue mass and classified as generalized or partial. We report a non-familial (sporadic) case of partial lipodystrophy caused by a novel genetic mechanism involving closely linked pathogenic variants in the gene.
Methods: A female adult with partial lipodystrophy and her parents were evaluated for gene variants across the exome under different mendelian inheritance models (autosomal dominant, recessive, compound heterozygous, and X-linked) to find pathogenic variants.
Facial lipoatrophy, a sign of normal aging, also occurs due to lipodystrophy from metabolic disorders affecting lipogenesis. It can be hereditary or acquired, localized or generalized. In HIV patients, prolonged antiretroviral therapy (ART) is a major cause, affecting around 55% of patients with 47% experiencing facial lipoatrophy.
View Article and Find Full Text PDFA case report of lupus panniculitis-induced facial lipoatrophy successfully treated with injectable hyaluronic acid.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, University of Calgary, Calgary, AB, Canada.
Article Synopsis
- Lupus panniculitis is a chronic form of cutaneous lupus that causes painful, firm nodules on areas like the legs, face, and trunk, potentially leading to scarring or loss of fat in those areas.
- Patients suffering from lipoatrophy due to lupus panniculitis may experience distress, and there is varying information on treating it with fat transfer or fillers.
- A case study highlights a 37-year-old woman who successfully restored volume in her right cheek using injectable hyaluronic acid filler after experiencing lipoatrophy following a period of stable disease.
Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review.
Einstein (Sao Paulo)
December 2024
Division of Plastic Surgery, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Agents that inhibit programmed cell death (IPD-1) in T lymphocytes are indicated for patients with advanced cancer. However, some individuals may develop endocrinological conditions, such as diabetes, thyroid dysfunction, and lipodystrophy, after treatment. This systematic review and case report of IPD-1 lipodystrophies describes a patient who received nivolumab treatment for advanced clear cell renal carcinoma and subsequently developed diabetes as well as facial and body lipodystrophy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!